The Epidemic

Two-Drug Regimen

The FDA approves Juluca, the first complete treatment regimen to treat those who are virologically suppressed.

BY VICTOR MELAMED

The U.S. Food and Drug Administration (FDA) has approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with HIV instead of three or more drugs included in standard HIV treatment.

Juluca is a fixed-dose tablet containing two previously approved drugs (dolutegravir and rilpivirine) to treat adults with HIV-1 infections whose virus is currently suppressed on a stable regimen for at least six months, with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.

“Limiting the number of drugs in any HIV treatment regimen can help reduce toxicity for patients,” said Debra Birnkrant, M.D., director of the Division of Antiviral Products in the FDA’s Center for Drug Evaluation and Research.

Juluca’s safety and efficacy in adults were evaluated in two clinical trials. Results showed Juluca was effective in keeping the virus suppressed and comparable to those who continued their current anti-HIV drugs.

The most common side effects in patients taking Juluca were diarrhea and headache. Serious side effects include skin rash and allergic reactions, liver problems and depression or mood changes. Juluca should not be given with other anti-HIV drugs and may have drug interactions with other commonly used medications.

The FDA granted approval of Juluca to ViiV Healthcare.

Share on FacebookTweet about this on TwitterShare on TumblrShare on LinkedInShare on Google+Email this to someone